ANEB Key Statistics, Chart & Performance
The current stock price of ANEB is 1.2 USD. In the past month the price decreased by -51.81%. In the past year, price decreased by -29.41%.
ANEB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.98 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 20.02 | 500.60B | ||
| MRK | MERCK & CO. INC. | 12.08 | 264.21B | ||
| PFE | PFIZER INC | 7.82 | 142.31B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.34 | 111.38B | ||
| ZTS | ZOETIS INC | 19.79 | 55.30B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.55 | 22.66B | ||
| VTRS | VIATRIS INC | 5.25 | 14.10B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.31 | 11.12B | ||
| CORT | CORCEPT THERAPEUTICS INC | 94.99 | 8.79B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.74B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.41B |
Related stock screener links
About ANEB
Company Profile
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the provision of pharmaceutical services. The company is headquartered in Lakeway, Texas and currently employs 2 full-time employees. The company went IPO on 2021-05-07. The company is engaged in developing treatments for cannabis toxicity, such as unintentional cannabis poisoning, acute cannabinoid intoxication (ACI) and the landscape of acute cannabis-induced conditions. Its lead product candidate is selonabant, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat cannabis toxicity. Selonabant is orally bioavailable, rapidly absorbed, and has also been formulated for intravenous administration. Selonabant is intended to rapidly reverse the negative effects of cannabis-induced toxicity and reduce time to recovery. The company is also prioritizing the advancement of a selonabant intravenous (IV) formulation as a potential treatment for pediatric patients with cannabis-induced CNS depression.
Company Info
ANEBULO PHARMACEUTICALS INC
C/O Anebulo Pharmaceuticals, Inc., 1017 Ranch Road 620 South, Suite 107
Lakeway TEXAS US
CEO: Daniel Schneeberger
Employees: 3
Phone: 17372035270
ANEBULO PHARMACEUTICALS INC / ANEB FAQ
Can you describe the business of ANEBULO PHARMACEUTICALS INC?
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the provision of pharmaceutical services. The company is headquartered in Lakeway, Texas and currently employs 2 full-time employees. The company went IPO on 2021-05-07. The company is engaged in developing treatments for cannabis toxicity, such as unintentional cannabis poisoning, acute cannabinoid intoxication (ACI) and the landscape of acute cannabis-induced conditions. Its lead product candidate is selonabant, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat cannabis toxicity. Selonabant is orally bioavailable, rapidly absorbed, and has also been formulated for intravenous administration. Selonabant is intended to rapidly reverse the negative effects of cannabis-induced toxicity and reduce time to recovery. The company is also prioritizing the advancement of a selonabant intravenous (IV) formulation as a potential treatment for pediatric patients with cannabis-induced CNS depression.
What is the stock price of ANEBULO PHARMACEUTICALS INC today?
The current stock price of ANEB is 1.2 USD. The price increased by 0.84% in the last trading session.
Does ANEBULO PHARMACEUTICALS INC pay dividends?
ANEB does not pay a dividend.
What is the ChartMill rating of ANEBULO PHARMACEUTICALS INC stock?
ANEB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about ANEBULO PHARMACEUTICALS INC (ANEB) stock?
6 analysts have analysed ANEB and the average price target is 8.16 USD. This implies a price increase of 580% is expected in the next year compared to the current price of 1.2.
Should I buy ANEB stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ANEB.
ANEB Technical Analysis
ANEB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ANEB. While ANEB has a great health rating, there are worries on its profitability.
ANEB Financial Highlights
Over the last trailing twelve months ANEB reported a non-GAAP Earnings per Share(EPS) of -0.23. The EPS increased by 23.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -69.86% | ||
| ROE | -72.78% | ||
| Debt/Equity | 0 |
ANEB Forecast & Estimates
6 analysts have analysed ANEB and the average price target is 8.16 USD. This implies a price increase of 580% is expected in the next year compared to the current price of 1.2.